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Abstract
Purpose Cognitive decline is commonly reported during the menopausal transition, with memory and attention being 
particularly affected. The aim of this study was to investigate the effects of a commercially available soy drink on cognitive 
function and menopausal symptoms in post-menopausal women.
Methods 101 post-menopausal women, aged 44–63 years, were randomly assigned to consume a volume of soy drink 
providing a low (10 mg/day; control group), medium (35 mg/day), or high (60 mg/day) dose of isoflavones for 12 weeks. 
Cognitive function (spatial working memory, spatial span, pattern recognition memory, 5-choice reaction time, and match 
to sample visual search) was assessed using CANTAB pre- and post-the 12 week intervention. Menopausal symptoms were 
assessed using Greene’s Climacteric Scale.
Results No significant differences were observed between the groups for any of the cognitive function outcomes measured. 
Soy drink consumption had no effect on menopausal symptoms overall; however, when women were stratified according 
to the severity of vasomotor symptoms (VMS) at baseline, women with more severe symptoms at baseline in the medium 
group had a significant reduction (P = 0.001) in VMS post-intervention (mean change from baseline score: − 2.15 ± 1.73) in 
comparison to those with less severe VMS (mean change from baseline score: 0.06 ± 1.21).
Conclusions Soy drink consumption had no effect on cognitive function in post-menopausal women. Consumption of 
~ 350 ml/day (35 mg IFs) for 12 weeks significantly reduced VMS in those with more severe symptoms at baseline. This 
finding is clinically relevant as soy drinks may provide an alternative, natural, treatment for alleviating VMS, highly prevalent 
among western women.
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Introduction
Cognitive decline is commonly reported by peri- and post-
menopausal women and deteriorations in memory; attention 
and processing speed have been observed during the meno-
pausal transition [1–4]. These effects have been attributed 
to a reduction in circulating estrogen concentrations [5]; 
albeit, this has been contested [6]. Hormone therapy (HT) 
remains the most effective treatment for vasomotor meno-
pausal symptoms (VMS) [7] and early observational studies 
supported a beneficial effect of HT on cognitive function 
[8]. Two recent intervention studies have demonstrated that 
HT initiated early in menopause has neither beneficial nor 
harmful effects on cognition [9, 10]. Furthermore, despite 
HT being commonly prescribed for otherwise healthy 
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young/early post-menopausal women, many refrain from 
HT use due to the health risks associated with HT use in 
older women [7, 11]. Alternatively, natural approaches for 
the treatment and prevention of menopausal symptoms are 
thus being sought.
Dietary soy isoflavones (IFs) have been reported to be 
efficacious in the treatment of hot flushes [12] and to have 
the potential to enhance cognitive function in post-menopau-
sal women, having the ability to cross the blood brain barrier 
in small amounts [13, 14]. Genistein and daidzein, the main 
IFs present in the soy bean, can bind to estrogen receptors 
(ERs), and are classified as selective ER modulators, having 
a higher affinity for ER-β than ER-α [15, 16]. ERs are local-
ised throughout the adult brain including the hippocampus, 
where ERβ is more highly expressed in comparison to ERα 
[17], and are also localised within the prefrontal cortex [5]. 
These areas are important for learning, memory, attention, 
and higher order cognitive function, and are particularly sus-
ceptible to age-related decline [18]. Both ER-mediated and 
non-ER-mediated neuroprotective effects have been demon-
strated for soy/IFs using in vitro and animal models [19, 20]. 
Such mechanisms include reduced neuronal loss, inhibition 
of β-amyloid-induced cell death, facilitation of cholinergic 
transmission, reduced free radical generation, anti-inflam-
matory and antioxidant effects [19, 21], and via the modula-
tion of mitochondrial function [20]. Furthermore, a high soy 
diet [22] and soy isoflavone supplementation [23] has been 
shown to improve cognitive function in men. Nevertheless, 
randomised-controlled trials investigating the effects of soy/
IFs on cognitive function in post-menopausal women have 
yielded inconsistent findings, with some showing positive 
effects on cognitive function [24–29] and others demonstrat-
ing null/negative effects [30–33]. Two recent comprehen-
sive reviews [19, 34] have highlighted several variations in 
study design that have likely contributed to these disparate 
outcomes including: age; time since menopause; habitual 
soy/IF intake; IF dose, duration, bioavailability and metabo-
lism, and cognitive function assessment. To date, only one 
study has investigated the effects of soy/IFs on cognitive 
function in post-menopausal women using a food (soy milk) 
[31] rather than a supplement. There is, therefore, a need for 
additional, well-designed studies to further assess the effects 
of IFs on cognitive function.
In line with the ‘critical window hypothesis’ of HT and 
cognitive function that postulates that optimal effects are 
evident with the early initiation [35], limited evidence sug-
gests that younger post-menopausal women (< 60 years) may 
gain more cognitive benefit from soy IFs in comparison to 
their older counterparts [25]. It has also been postulated that 
the effects of soy on health may be determined by an indi-
vidual’s equol producer status [36]. S-equol, a potent ligand 
for ERβ, is an isoflavan formed exclusively via the bacte-
rial conversion of daidzein in the intestine [37] and is only 
produced by ~ 30% of western populations following a soy 
challenge [38–40]. The ability to produce equol has been 
associated with reduced VMS [41]. Furthermore, S-equol 
supplementation alleviates hot flushes [42] and S-equol 
derivatives of soy IFs are now recommended by the North 
American Menopause Society for the non-hormonal man-
agement of VMS [43], who have highlighted the need for 
further studies in this area.
The aim of this study was to investigate the effects of a 
commercially available soy drink on cognitive function and 
menopausal symptoms in post-menopausal women within 
7 years postmenopause. A secondary aim was to assess the 
relationship between equol producer status and cognitive 
function and menopausal symptoms.
Subjects and methods
Design
This 12-week parallel group, randomised, controlled trial 
was conducted between October 2015 and May 2018. All 
procedures were approved by Ulster University’s Research 
Ethics Committee (REC/15/0025) and the study was regis-
tered at http://www.clini caltr ials.gov (NCT03561662). Par-
ticipants were recruited throughout the province of Ulster 
and screening, baseline and post-intervention appointments 
were conducted before and after the 12-week interven-
tion either at the university, the participant’s home, or at 
a location convenient for the participant. The duration of 
intervention was based on previous intervention studies 
in post-menopausal women that have demonstrated that 
soy IF supplementation (60 mg/day) for 6 weeks signifi-
cantly improves frontal lobe function [26], with significant 
improvements in sustained attention and long-term episodic 
memory additionally observed when supplementation is 
extended to 12 weeks [24]. The primary outcome of the 
study was effect on cognitive function and the secondary 
outcome was effect on menopausal symptoms. Sub-analysis 
investigated the effect of the intervention based on severity 
of VMS at baseline and also investigated cognitive func-
tion and menopausal symptoms according to equol producer 
status.
Participants
Eligible participants were apparently healthy women within 
7 year postmenopause (i.e., 1–7 years since last menstrual 
period). Post-menopausal status was confirmed based on 
a serum concentration of follicle-stimulating hormone 
(FSH) > 30 mIU/ml (assessed via electrochemiluminescence 
immunoassay on a Cobas 8000 analyzer [Cobas 602 mod-
ule], Roche Diagnostics at Antrim Area hospital). Exclusion 
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criteria included: surgically induced menopause; habitual 
consumers of soya foods (> 2 serves/week); current use of 
HT or IF supplements; antibiotics use within the previous 
3 months; current use of psychoactive medication; presence 
or history of cardiovascular disease, cancer, diabetes, thy-
roid, renal or kidney disease, alcohol or drug abuse; cog-
nitive impairment as determined by a Mini-Mental State 
Examination score < 24; psychiatric distress as determined 
using a General Health Questionnaire-28 [44] score of ≥ 26; 
red–green colour blind, assessed via the Ishihara test (as 
CANTAB testing requires colour recognition); abnormal full 
blood profile (assessed via a Sysmex KX21-N, Sysmex Ltd, 
UK at Ulster University); and/or insufficient renal/hepatic 
performance assessed via kidney and liver function tests 
(assessed photometrically via a Cobas 6000 analyzer [Cobas 
C501 module], Roche Diagnostics at Causeway Hospital).
Intervention
An independent clinical trial manager used MINIM software 
[45] to randomise recruited women to one of the three treat-
ment groups with an allocation ratio of 1:1:1. Participants 
were asked to consume soy drinks  (Alpro®) providing a 
low (10 mg), medium (35 mg), or high (60 mg) dose of IFs 
daily for a period of 12 weeks and could choose from differ-
ent flavours of drink (original, unsweetened, chocolate, or 
strawberry). Limited evidence suggests that IFs consumed in 
divided doses may be more effective in alleviating menopau-
sal symptoms than a single dose [46, 47], and thus, women 
were advised to spread their intake throughout the day. The 
group that consumed the lowest dose of IFs was considered 
a low-dose control group as beneficial effects of soy IFs on 
post-menopausal health have previously been observed in 
intervention studies at much higher doses [48]; furthermore, 
it was not possible to obtain a placebo control drink. The 
previous soy/IF intervention studies on cognitive function 
in post-menopausal women have used doses ranging from 
60 to 160 mg IFs per day [24–33]. This study utilised a dose 
that was achievable in a commercially available soy drink 
and at a volume that was easily incorporated into an indi-
vidual’s daily diet. Compliance was monitored by measuring 
plasma concentrations of soy IFs. Total genistein, daidzein, 
and equol concentrations were assessed using LC–MS/MS 
by LGC Limited (Cambridgeshire, UK). Equol producers 
were defined as those with a plasma equol concentration of 
> 20 nmol/l (5 µg/l) [40].
Dietary intake, anthropometrics, and general health 
and lifestyle
Weight (kg) and height (cm) were measured at baseline 
and used to calculate BMI [weight (kg)/height (m)2]. Body 
weight was measured to the nearest 0.1  kg using Seca 
770 electronic weighing scales (Brosch Direct Ltd, Peter-
borough, United Kingdom), without footwear and heavy 
clothing. Standing body height was measured to the near-
est 0.1 cm using a Seca 220 stadiometer (Seca Ltd, Ham-
burg, Germany). The participant stood without footwear, 
with their heels together, hands and arms hanging relaxed, 
and measurements were taken with the Frankfurt plane in a 
horizontal position. Dietary intake was assessed at baseline 
and post-intervention using a 4-day food diary. Participants 
received instructions on how to complete the diary from 
a trained researcher and dietary intake was analysed using 
Nutritics nutritional analysis software [49]. A general health 
and lifestyle questionnaire were completed by participants 
at baseline and provided information on age, gender, marital 
status, education level, occupation, smoking habits, alcohol 
use, dietary habits, and physical activity.
Blood collection and processing
Fasted blood samples were collected by a trained phle-
botomist before and after intervention for the analysis of 
serum FSH and plasma IF concentrations. Participants 
were instructed to fast from 10 pm the night prior to blood 
sampling and water intake was encouraged. Fasted blood 
samples were obtained from the antecubital fossa using a 
21-gauge butterfly needle and 8 ml serum and 9 ml ethyl-
enediametetraacetic acid (EDTA) plasma vacutainer tubes 
(Greiner Bio-One GmbH, Kremsmunster, Austria). Fol-
lowing inversion, serum samples were allowed to clot for 
> 60 min and plasma samples placed in refrigeration until 
full blood profile analysis. Following this, all tubes were 
centrifuged at 2200 rpm for 15 min at 4 °C to allow the sepa-
ration of whole blood into its respective components. Fol-
lowing separation, serum and plasma samples were divided 
into aliquots and stored at − 80 °C until further analysis.
Cognitive function
Pre- and post-intervention cognitive function was assessed 
in the morning, after participants had consumed a standard, 
caffeine-free, breakfast. Cognitive function was assessed 
using the Cambridge Neuropsychological Test Automated 
Battery (CANTAB Research Suite; Cambridge Cognition, 
UK) [50]. CANTAB has been extensively validated for 
assessing brain-to-behaviour relationships in adult popula-
tions [51, 52], has proven test–retest reliability [53], and 
is deemed suitable for use with older adults [51]. The fol-
lowing tests were used: spatial working memory (SWM), 
spatial span (SSP), pattern recognition memory (PRM), 
5-choice reaction time (RTI), and match to sample visual 
search (MTS). The tests chosen activate areas of the brain 
that are associated with cognitive decline during the meno-
pausal transition and that are sensitive to hormonal changes, 
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including the hippocampus [54] and prefrontal cortex [5]. 
SWM and SSP activate the temporal and frontal lobe regions 
of the brain; PRM activates the temporal lobe, hippocam-
pus and amygdala; RTI and MTS activate the fronto-striatal 
circuitry [55]. The procedure for assessing SSP, RTI, and 
MTS is described in detail elsewhere [56]. Spatial work-
ing memory (SWM), a sensitive measure of frontal lobe 
and executive function, requires retention and manipula-
tion of visuospatial information. The test began with four 
coloured squares (boxes) shown on the screen. Participants 
were required, by selecting boxes and using a process of 
elimination, to find one blue ‘token’ in each of four boxes 
(only one token is hidden at a time) and use them to fill 
up an empty column on the right-hand side of the screen. 
Touching any box in which a token has already been found 
is an error. The trial was then repeated three times with four 
boxes and then progressed to four trials with six boxes and 
four trials with eight boxes. The colour and position of the 
boxes used are changed from trial to trial to discourage the 
use of stereotyped search strategies and a practice test was 
completed prior to testing. The outcome measure was SWM 
total errors, i.e., the number of times which a box is selected 
that is certain not to contain a token and, therefore, should 
have not been visited by the participant.
Visual memory was assessed using the Pattern Recogni-
tion Memory (PRM) test in a two-choice forced discrimina-
tion paradigm. Participants were asked to remember a series 
of 12 abstract-coloured patterns; each presented for 3 s. They 
were then presented with a series of 12 pairs of old–new pat-
terns and were asked to touch the pattern seen previously in 
each case. This procedure was repeated with a second set of 
12 patterns followed by 12 pairs of patterns for recognition. 
The outcome measure was mean correct latency, i.e., the 
mean time (milliseconds) to respond correctly.
Menopausal symptoms
The Greene Climacteric Scale [57] was used to assess men-
opausal symptoms at baseline and post-intervention. This 
21-item scale provides three main independent measures of 
psychological, somatic, and vasomotor symptoms. Partici-
pants were asked to indicate the extent to which they were 
currently bothered by the list of symptoms on a scale from 
1 ‘not at all’ up to 4 ‘extremely’.
Statistical analyses
An a priori power calculation was conducted using spatial 
working memory total error data obtained from the study 
of Thompson et al. [58]. Based on the probability of a type 
1 error (α) = 0.05 and a Power of 0.9, 41 participants were 
required in each group to be able to reject the null hypothesis 
that the population means of the treatment groups are equal. 
To allow for dropouts, we aimed to recruit 150 women to 
the study. All statistical analyses were performed using the 
Statistical Package for the Social Sciences (SPSS) with sig-
nificance set at P < 0.05 throughout (IBM SPSS Statistics for 
Windows, version 24.0, IBM Corp, Armok NY). Only those 
participants that had completed cognitive testing at both 
baseline and post-intervention were included in the analy-
sis. Intention-to-treat analysis was also performed including 
all participants randomised at baseline and did not change 
the primary outcome findings. The Shapiro–Wilk test was 
used to determine whether data followed a normal distribu-
tion and skewed variables were log-transformed to attain a 
normal distribution prior to analysis or analysed using non-
parametric statistical tests. Transformations were applied to 
SWM, SSP, PRM, RTI, and MTS data. Descriptive statistics 
were used to present participant characteristics at baseline. 
The effect of intervention on the primary outcome measures 
of cognitive function (SWM, SSP, PRM, RTI, and MTS) 
was analysed using an analysis of covariance (ANCOVA) 
with baseline measures included as covariates. The second-
ary outcome measure of menopausal symptoms was ana-
lysed using a Kruskal–Wallis test. IF concentrations were 
compared between groups using a Kruskal–Wallis test with 
post hoc analysis conducted using a Mann–Whitney U test. 
Two outliers with post-intervention genistein concentrations 
of > 800 ng/ml in the low-dose treatment group and one in 
the high-dose group (baseline genistein of 275 ng/ml) were 
removed prior to statistical analysis of IF concentrations 
between groups. Sub-analysis was conducted to determine 
if the effect of the intervention on cognitive function and 
menopausal symptoms was significantly different between 
equol producers and non-producers using a Mann–Whitney 
U test. This test and one-way ANOVA with quadratic con-
trasts were also used in sub-analysis to investigate the effect 
of the intervention on VMS stratifying women according to 
severity of VMS at baseline. Dietary intake pre- and post-
intervention was analysed using the Wilcoxin Signed-Rank 
test.
Results
A total of 101 post-menopausal women completed the study 
and were included in the final analysis. Participant progress 
through the study is illustrated in the CONSORT diagram 
[59] in Fig. 1. Baseline demographic characteristics of the 
study participants are shown in Table 1. There was no sig-
nificant difference at baseline between the groups for any of 
the characteristics presented. Table 2 shows the effect of the 
intervention on cognitive function; no significant differences 
were observed between the groups for any of the cognitive 
function outcomes measured (RTI, SSP, SWM, PRM, and 
MTS). The soy drink had no effect on menopausal symptoms 
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overall (Table 3); however, when women were stratified 
according to the severity of their VMS (hot flushes and 
night sweats) at baseline by splitting into two groups above/
below mean, women with more severe VMS at baseline in 
the medium group had a significant reduction in symptoms 
after consuming the soy drink for 12 weeks, in comparison 
to those with less severe symptoms at baseline (Table 4). 
There was a significant quadratic trend for dose (P = 0.011) 
with the observed reduction in symptoms in the medium-
dose group being significantly greater in comparison to that 
observed in women with more severe VMS at baseline in 
the low-dose control group (P = 0.018) and the high-dose 
group (P = 0.046).
Compliance, as assessed via plasma IF concentrations, 
appeared good (Table 5), albeit some women found it dif-
ficult to consume the instructed volume of soy drink in the 
high-dose group, with seven women failing to complete the 
intervention for this reason. Blood samples were available 
for IF analysis for 95 participants at baseline and 87 post-
intervention. IF concentrations were not significantly differ-
ent between groups at baseline. As expected, post-interven-
tion genistein concentration was significantly higher in the 
Assessed for Eligibility (n=394)
Excluded (n=279)
Not meeng inclusion criteria (n=146)
Declined to parcipate (n=133)
Randomized (n=115)
Allocaon
Follow-Up
Analysis
Allocated to 60mg/day (n=38)
Received allocated
intervenon (n=38)
Disconnued intervenon (n=4)
Illness (n=2)
Anbiocs (n=2)
Analysed 10 mg/d (n=35) Analysed 35mg/d (n=37) Analysed 60mg/d (n=29)
Enrolment
Allocated to 35mg/day (n=38)
Received allocated
intervenon (n=38)
Allocated to 10mg/day (n=39)
Received allocated
intervenon (n=39)
Disconnued intervenon (n=1)
No longer wished to parcipate
(n=1)
Disconnued intervenon (n=9)
Could not consume volume of
drink required (n=7)
Family illness (n=1)
Illness (n=1)
Fig. 1  CONSORT diagram of participant flow. A total of 394 women 
were assessed for eligibility with 279 excluded due to not meeting the 
inclusion criteria (n = 146) or not wishing to participate in the study 
(n = 133). Remaining post-menopausal women were randomised to 
receive a soy drink  (Alpro®) and asked to consume a volume pro-
viding either 10  mg (n = 39), 35  mg (n = 38) or 60  mg (n = 38) IFs 
daily. A total of 14 participants were lost to follow up owing to illness 
(n = 3) unrelated to the intervention, antibiotic use (n = 2), no longer 
wishing to participate (n = 1), family illness (n = 1) or being unable to 
consume the soy drink (n = 7). A total of 101 women completed the 
study and were included in the final analysis
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medium- (P = 0.007) and high-dose (P = 0.013) groups in 
comparison to the low-dose group. Post-intervention daid-
zein was also significantly higher in the medium- (P = 0.006) 
and high-dose (P = 0.029) groups versus the low group. 
There was no significant difference in post-intervention IF 
concentrations between the medium- and high-dose groups. 
Some 28.7% of the cohort was classified as equol produc-
ers with n = 7, n = 9, and n = 9 participants classified as 
equol producers within the low-, medium-, and high-dose 
groups, respectively. In sub-analysis, cognitive performance 
was not significantly different according to equol status 
(Table 6) albeit, within the high-dose group, spatial working 
memory improved in equol producers (change from base-
line − 9.44 ± 15.69, n = 9) in comparison to non-producers 
(2.36 ± 13.24, n = 23), though this effect did not reach sig-
nificance (P = 0.066). VMS were significantly lower in equol 
producers in comparison to non-producers at both baseline 
(3.67 ± 1.01 vs 4.49 ± 1.60, P = 0.022) and post-intervention 
(2.96 ± 1.04 vs 3.86 ± 1.67, P = 0.046).
Table 1  Baseline participant characteristics
Characteristics were not significantly different between treatment 
groups
FSH follicle-stimulating hormone, GHQ-28 General Health Ques-
tionnaire-28, LMP time since last menstrual period, METs metabolic 
equivalents, MMSE mini-mental state examination, PA physical activ-
ity
a Data on smoking, alcohol use, education, and physical activity 
were unavailable for 4 participants (n = 1, n = 2 and n = 1 in the low-, 
medium-, and high-dose groups, respectively) as they failed to com-
plete the health and lifestyle questionnaire
b Mean ± SD (all such values with the exception of smoking and edu-
cation)
Measurea Soy IF treatment group
Low (n = 35) Medium (n = 37) High (n = 29)
Age (years) 53.69 ± 3.72b 53.86 ± 3.28 53.72 ± 4.62
Height (m) 1.61 ± 0.065 1.64 ± 0.062 1.63 ± 0.073
Weight (kg) 70.32 ± 12.36 71.48 ± 13.85 72.91 ± 14.86
BMI (kg/m2) 26.97 ± 5.22 26.76 ± 5.73 27.37 ± 5.77
Non-smokers (%) 94.12 100 100
Alcohol (units/
week)
7.64 ± 6.58 11.73 ± 12.60 7.44 ± 10.21
Education level (n)
 Primary 0 1 0
 Secondary 19 13 12
 Tertiary 15 21 16
PA (METs/week) 165.17 ± 56.32 184.70 ± 57.48 192.74 ± 76.98
LMP (months) 31.97 ± 19.05 39.33 ± 21.99 39.38 ± 23.25
FSH (IU/ml) 83.02 ± 34.44 88.79 ± 28.33 85.84 ± 33.84
GHQ-28 16.91 ± 4.82 14.73 ± 5.48 15 ± 4.6
MMSE 29.17 ± 0.79 29.03 ± 1.07 29.21 ± 0.73
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Energy intake, carbohydrate, protein, and total fat intake 
were not significantly different between the low-, medium-, 
and high-dose groups at baseline or post-intervention 
(Table 7). In the high-dose group, protein and total fat intake 
(expressed as % energy intake) were significantly lower post-
intervention in comparison to baseline. Using the Goldberg 
cut-off technique [60], 12.8% and 15.7% of participants were 
identified as mis-reporters at baseline and post-intervention, 
respectively. Of these, three were within the low, two within 
the medium, and five within the high-dose groups at baseline 
with six within the low, two within the medium, and three 
within the high-dose groups post-intervention.
Discussion
In the current study, consumption of a soy drink for 
12 weeks, providing 35 or 60 mg of IFs/day, had no effect on 
visual memory, working memory, or attention, in apparently 
healthy post-menopausal women in comparison to consump-
tion of a low-dose control providing 10 mg IFs/day. We did 
not observe a significant effect for menopausal symptoms; 
albeit, sub-analysis identified a potential beneficial effect 
of soy IFs in women with more severe VMS at baseline. 
Our findings on cognitive function are in agreement with 
the previous studies that observed no beneficial effects of 
isoflavone supplementation on cognition in post-menopausal 
women [30, 32, 33]. In contrast, others have demonstrated 
an improvement in frontal lobe function (mental flexibility 
and planning) [24, 26], long-term episodic memory, sus-
tained attention [24], psychomotor performance [27], verbal/
semantic memory [25], and visual memory [29]. Variations 
in study design make it difficult to draw direct comparisons 
between the findings of our study and previous work. Mixed 
results may be reflective of the different cognitive tests used. 
Although two studies, showing beneficial effects, utilised 
CANTAB to assess cognitive function [24, 26], neither used 
the same tests as the current study. Given the wide range 
of methodologies currently available to assess cognitive 
function, there is a need to identify a standard method and 
testing suite to enable a better comparison between stud-
ies and reliably inform scientific knowledge in this area. 
Conflicting results may also be reflective of variation in the 
dose and duration of isoflavone supplementation used. Three 
studies that report improvements in cognitive function with 
soy IF supplementation have used much higher doses and/
or have intervened over a longer duration than that used in 
the current study [25, 27, 29]. Furthermore, age/time since 
menopause may be a key factor in determining response to 
soy isoflavones, with Kritz-Silverstein et al. [25] observ-
ing significant effects on a test of visumotor tracking and 
attention in younger (50–59 years) but not older women 
(60–74 years). Kreijkamp-Kaspers et al. also observed no Ta
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significant effects using the same test in a cohort of older 
post-menopausal women, aged 60–75 years [30]. In the 
longest intervention trial conducted to date, supplementa-
tion of 91 mg IFs daily for 2.5 years had no effect on global 
cognition, executive function, or verbal episodic memory in 
healthy post-menopausal women albeit, an improvement in 
a visual memory factor was observed [29]. In contrast to our 
study, there was a wide age range in this study (45–92 years) 
with almost half of the cohort > 10 years postmenopause; 
sub-analysis suggested that such women were less likely to 
show cognitive improvement and this may, therefore, have 
influenced the null findings in this study. Finally, differences 
in the makeup of the supplement used, in terms of the indi-
vidual isoflavone constituents, may account for the observed 
mixed findings on cognition. Genistein and daidzein have 
distinct biological effects, e.g., genistein is a potent inhibi-
tor of protein tyrosine kinase (PTK) [61], whereas daidzein 
is not a PTK inhibitor [62]. Genistein is now thought more 
promising as a treatment for Alzheimer’s disease [63–65].
To our knowledge, only one other study has investigated 
the effects of IFs on post-menopausal cognition in the form 
of a soy drink [31]. In this study, consumption of IFs via 
a drink (72 mg/day) or a supplement (70 mg/day) over 
16 weeks did not improve short-term memory, long-term 
memory, working memory, or selective attention as assessed 
using tests similar to those used in our study. The soy milk 
group showed a poorer performance in verbal working mem-
ory in comparison to the supplement and control groups; 
albeit this study was subject to limitations including subjec-
tive compliance, lack of power, and lack of controls, owing 
to the quasi-experimental design.
In agreement with the previous literature, 28.7% of our 
study cohort were equol producers [38–40]. Limited evi-
dence suggests that the ability to produce equol may confer 
beneficial effects on cognitive function following soy intake 
[66, 67], potentially via increased cerebral blood flow [68]. 
We did not observe any significant differences in cognitive 
performance following intervention between equol pro-
ducers and non-producers, although, within the high-dose 
group, improvements in spatial working memory in produc-
ers versus non-producers were approaching significance. Our 
findings support those of Henderson et al. [29] who observed 
a nonsignificant trend towards improved global cognition in 
consistent equol producers. Similar to Henderson’s study, 
the sample size in the current study was likely too small to 
adequately investigate the role of equol in cognitive perfor-
mance and further research in this area is warranted.
In agreement with our findings, previous studies, includ-
ing 2 that used the same scale as that in the current study 
[24, 26], have reported no effect of IF supplementation on 
menopausal symptoms [24, 26, 32]. Basaria et al. observed 
an improvement in menopausal symptoms using the men-
opause-specific quality-of-life questionnaire; however, the Ta
bl
e 
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dose used in this study was very high (160 mg/day) [33]. 
A recent meta-analysis has demonstrated that soy IF sup-
plementation can significantly reduce hot flush frequency 
and severity in comparison to placebo, with supplements 
containing > 18.8  mg of genistein being most effective 
[12]. In support of these findings, our study has shown that 
women with more severe VMS at baseline showed a signifi-
cant improvement in symptoms following consumption of 
35 mg IFs/day (providing ~ 18 mg genistein) in comparison 
to those consuming 10 mg/day. This observation was not 
replicated in the high-dose group, possibly due to the sample 
size, and thus, further studies are required to confirm these 
findings. Our findings in the medium group are in agreement 
with an open-label crossover study that demonstrated a com-
mercial soy drink  (ViveSoy®), providing ~ 50 mg IFs per 
day for 12 weeks, improved climacteric symptoms including 
hot flushes in peri/post-menopausal women [69]. Previous 
research on the effects of soy foods on menopausal symp-
toms is limited [70] and our findings warrant further study in 
this area. In support of the role of S-equol in the alleviation 
Table 5  IF concentrations at baseline and following 12 weeks’ soy drink intervention
BLD below limit of detection
a Mean ± SD (all such values)
A,B Values with different superscript letters across a row are significantly different (Kruskal–Wallis with post hoc Mann–Whitney U test)
Treatment group Low Medium High
Baseline (n = 32) Week 12 (n = 32) Baseline (n = 35) Week 12 (n = 32) Baseline (n = 28) Week 12 (n = 23)
Genistein (ng/ml) 10.01 ± 22.07a 82.75 ± 124.62A 9.83 ± 24.25 168.71 ± 166.81B 6.40 ± 9.27 216.71 ± 305.36B
Daidzein (ng/ml) 5.03 ± 11.88 20.44 ± 30.82A 2.29 ± 4.37 39.20 ± 36.9B 2.50 ± 3.34 49.82 ± 66.49B
Equol (ng/ml) 1.76 ± 6.01 3.81 ± 8.17A BLD 9.43 ± 19.84A 0.42 ± 1.30 11.69 ± 19.23A
Table 6  Effect of soy drink intervention on cognitive performance 
stratifying women according to equol producer status
RTI five-choice reaction time measured as reaction time latency (ms), 
SSP spatial span measured as the longest sequence length recalled 
correctly, SWM spatial working memory measured as total errors 
made, PRM pattern recognition memory measured as mean correct 
latency (ms), MTS match to sample visual search measured as mean 
correct reaction time (ms)
a Defined as plasma equol concentration > 20 nmol/l (5 µg/l)
b Independent samples t test or Mann–Whitney U test for non-para-
metric data
c Mean ± SD (all such values)
Cognitive test Change from baseline Pb
Equol non-producers Equol  producersa
n = 62 n = 25
RTI 6.23 ± 54.98c − 6.23 ± 41.30 0.764
SSP 0.21 ± 1.34 0.12 ± 1.42 0.735
SWM − 1.82 ± 15.34 − 6.16 ± 16.36 0.245
PRM − 45.58 ± 533.00 − 62.66 ± 557.10 0.453
MTS − 363.39 ± 675.51 − 163.99 ± 630.38 0.234
Table 7  Dietary intake at baseline and following 12 weeks’ soy drink intervention
Nutrient intake did not differ between the groups at either baseline or post-intervention (Kruskal–Wallis test)
EI energy intake
a Wilcoxon signed-rank test comparing week 12 to baseline within groups
b Mean ± SD (all such values)
Treatment 
group
Low Medium High
Baseline 
(n = 27)
Week 12 
(n = 28)
Pa Baseline 
(n = 27)
Week 12 (n = 21) P Baseline 
(n = 24)
Week 12 
(n = 21)
P
Energy (Kcal/
day)
1532 ± 451.72b 1506 ± 526.37 0.715 1623 ± 549.91 1792.62 ± 665.34 0.845 1562 ± 501.51 1731 ± 583.89 0.163
Carbohydrate 
(g/day)
165.52 ± 47.76 154.21 ± 46.65 0.144 165.67 ± 44.26 162.43 ± 50.24 0.500 173.38 ± 63.37 170.00 ± 54.52 0.472
Protein (g) 74.74 ± 42.49 72.39 ± 24.59 0.726 75.85 ± 33.37 71.90 ± 28.28 0.184 77.21 ± 27.46 70.71 ± 32.31 0.139
Fat (g) 61.07 ± 25.96 59.86 ± 18.31 0.935 59.56 ± 16.74 65.40 ± 23.34 0.887 61.21 ± 23.32 59.00 ± 25.08 0.868
Carbohydrate 
(% EI)
44.32 ± 9.85 45.74 ± 28.91 0.068 42.52 ± 8.99 37.60 ± 7.82 0.184 44.26 ± 5.31 41.00 ± 11.35 0.744
Protein (% EI) 15.55 ± 2.55 18.28 ± 12.52 0.563 15.27 ± 3.42 15.37 ± 5.84 0.500 15.46 ± 2.13 13.59 ± 3.67 0.018
Fat (% EI) 42.76 ± 17.35 47.89 ± 25.98 0.503 42.11 ± 11.52 38.67 ± 12.85 0.112 46.94 ± 19.53 37.71 ± 13.52 0.022
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of VMS [41], equol producers in the current study had sig-
nificantly lower VMS scores throughout in comparison to 
non-equol producers.
Strengths of this study include the use of CANTAB, 
a well-validated method in digital cognitive assessment. 
CANTAB is a sensitive method to detect changes in cogni-
tive domains, including spatial memory, executive func-
tion, and information processing, in response to nutrition 
intervention trials, including soy isoflavone trials [71]. 
Despite being a more sensitive measure, one limitation of 
this method, highlighted within a recent International Life 
Sciences Institute (ILSI) review [71], is the speed/accu-
racy trade-offs associated with the more complex informa-
tion processing tasks available within computerized test 
batteries as well as training/practice effects in compari-
son to simple information processing tasks. In the current 
study, cognitive assessment was conducted 12 weeks apart, 
and thus, training/practice effects would be negligible. 
Cognitive assessment was strictly controlled with partici-
pants consuming the same standard caffeine-free breakfast 
prior to testing at both timepoints. Time since menopause 
was kept within a defined limit of < 7 years and compli-
ance was closely monitored. The main limitations of the 
study were the absence of a placebo control and the non-
blinded study design. Nonetheless, the low-dose control 
drink provided only 10 mg IFs/day, an amount well below 
that typically consumed in Asian populations (~ 25–50 mg/
day) [72] and well below the lowest dose previously used 
in intervention studies on cognitive function in post-men-
opausal women (60 mg/day) [24, 26, 27]. Given that we 
used a commercially available soy drink in the current 
intervention study, we were limited with regard to the dose 
of IFs that could be tested. Nonetheless, it is important to 
investigate the effects of soy foods in addition to IF supple-
ments as consumers may gain additional nutritional bene-
fits from consuming soy food as part of a healthy balanced 
diet [73]. Furthermore, IF pharmacokinetics are similar 
following ingestion of soy foods and IF supplements [74]. 
We did not reach our recruitment target of 41 participants/
group, largely due to participants not meeting the stringent 
inclusion criteria (of note was the substantial number of 
post-menopausal women currently on antidepressants); 
however, the study was still adequately powered (80% 
power) to detect significant effects. Reference ranges are 
not provided for the CANTAB tests used for healthy popu-
lations; however, our data concur with a previous study in 
healthy older women [75].
Our participants were apparently healthy and relatively 
early post-menopausal (< 7 years; mean 3.05 ± 1.78 years 
post-menopausal) and our findings are, therefore, not repre-
sentative of all post-menopausal women. Women > 7 years 
post-menopausal are less likely to be prone to fluctuating 
hormone levels and associated menopausal symptoms [76]. 
Furthermore, our findings cannot be extrapolated to post-
menopausal women suffering mild cognitive impairment; 
further research in this area is needed.
In conclusion, a commercially available soy drink had 
no effect on cognitive function in post-menopausal women. 
Consumption of ~ 350 ml/day (providing 35 mg IFs) for 
12 weeks significantly reduced VMS in those women with 
more severe symptoms at baseline, a finding with potential 
clinical relevance that warrants further research given the 
high prevalence of VMS in western women [77, 78].
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